CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
It affects up to 10 per cent of women of reproductive age around the world
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Subscribe To Our Newsletter & Stay Updated
